Wang Qinrong, Gou Xuanjing, Liu Lingling, Deng Daolan, Zhao Yan, Zhou Jianjiang, Xie Yuan, Jiang Yinhui, Li Jianglun, Zhang Jian, Liu Ying
Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, 9 Beijing Road, Guiyang, Guizhou, 550004, P. R. China.
Department of Thoracic Surgery, The Affiliated Hospital of Guizhou Medical University, 28 Beijing Road, Guiyang, Guizhou, 550004, P. R. China.
Cancer Cell Int. 2025 Jan 13;25(1):10. doi: 10.1186/s12935-025-03638-9.
XB130, a classical adaptor protein, exerts a critical role in diverse cellular processes. Aberrant expression of XB130 is closely associated with tumorigenesis and aggressiveness. However, the mechanisms governing its expression regulation remain poorly understood. Heterogeneous nuclear ribonucleoprotein C (hnRNPC), as an RNA-binding protein, is known to modulate multiple aspects of RNA metabolism and has been implicated in the pathogenesis of various cancers. We have previously discovered that hnRNPC is one of the candidate proteins that interact with the 3' untranslated region (3'UTR) of XB130 in non-small cell lung cancer (NSCLC). Therefore, this study aims to comprehensively elucidate how hnRNPC regulates the expression of XB130 in NSCLC.
We evaluated the expression of hnRNPC in cancer and assessed the correlation between hnRNPC expression and prognosis in cancer patients using public databases. Subsequently, several stable cell lines were constructed. The proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of these cells were detected through Real-time cellular analysis, adherent colony formation, wound healing assay, invasion assay, and Western blotting. The specific regulatory manner between hnRNPC and XB130 was investigated by Real-time quantitative PCR, Western blotting, RNA pull‑down assay, dual‑luciferase reporter assay, RNA immunoprecipitation, and Co-Immunoprecipitation.
We identified that hnRNPC expression is significantly elevated in NSCLC and correlates with poor prognosis in patients with lung adenocarcinoma. HnRNPC overexpression in NSCLC cells increased the expression of XB130, subsequently activating the PI3K/Akt signaling pathway and ultimately promoting cell proliferation and EMT. Additionally, overexpressing XB130 in hnRNPC-silenced cells partially restored cell proliferation and EMT. Mechanistically, hnRNPC specifically bound to the 3'UTR segments of XB130 mRNA, enhancing mRNA stability by inhibiting the recruitment of nucleases 5'-3' exoribonuclease 1 (XRN1) and DIS3-like 3'-5' exoribonuclease 2 (DIS3L2). Furthermore, hnRNPC simultaneously interacted with the eukaryotic initiation factor 4E (eIF4E), a component of the eIF4F complex, facilitating the circularization of XB130 mRNA and thereby increasing its translation efficiency.
HnRNPC overexpression promotes NSCLC progression by enhancing XB130 mRNA stability and translation, suggesting that hnRNPC might be a potential therapeutic and prognostic target for NSCLC.
XB130是一种经典的衔接蛋白,在多种细胞过程中发挥关键作用。XB130的异常表达与肿瘤发生和侵袭性密切相关。然而,其表达调控的机制仍知之甚少。异质性核核糖核蛋白C(hnRNPC)作为一种RNA结合蛋白,已知可调节RNA代谢的多个方面,并与多种癌症的发病机制有关。我们之前发现hnRNPC是在非小细胞肺癌(NSCLC)中与XB130的3'非翻译区(3'UTR)相互作用的候选蛋白之一。因此,本研究旨在全面阐明hnRNPC如何调节NSCLC中XB130的表达。
我们使用公共数据库评估了hnRNPC在癌症中的表达,并评估了hnRNPC表达与癌症患者预后之间的相关性。随后,构建了几种稳定的细胞系。通过实时细胞分析、贴壁集落形成、伤口愈合试验、侵袭试验和蛋白质免疫印迹法检测这些细胞的增殖、迁移、侵袭和上皮-间质转化(EMT)。通过实时定量PCR、蛋白质免疫印迹法、RNA下拉试验、双荧光素酶报告基因试验、RNA免疫沉淀和免疫共沉淀研究hnRNPC与XB130之间的具体调控方式。
我们发现hnRNPC在NSCLC中的表达显著升高,并且与肺腺癌患者的不良预后相关。NSCLC细胞中hnRNPC的过表达增加了XB130的表达,随后激活PI3K/Akt信号通路,最终促进细胞增殖和EMT。此外,在hnRNPC沉默的细胞中过表达XB130部分恢复了细胞增殖和EMT。机制上,hnRNPC特异性结合XB130 mRNA的3'UTR片段,通过抑制核酸酶5'-3'外切核糖核酸酶1(XRN1)和DIS3样3'-5'外切核糖核酸酶2(DIS3L2)的募集来增强mRNA稳定性。此外,hnRNPC同时与真核起始因子4E(eIF4E)相互作用,eIF4E是eIF4F复合物的一个组成部分,促进XB130 mRNA的环化,从而提高其翻译效率。
hnRNPC过表达通过增强XB130 mRNA稳定性和翻译促进NSCLC进展,提示hnRNPC可能是NSCLC潜在的治疗和预后靶点。